SillaJen Biotherapeutics is a publicly traded, clinical-stage biotech company headquartered in Korea with a US presence, developing novel anticancer drugs. SillaJen is investigating BAL0891, a first-in-class threonine tyrosine kinase/polo-like kinase 1 (TTK/PLK1) dual mitotic checkpoint inhibitor designed for the treatment of advanced solid tumors and r/r AML currently in Phase 1 clinical trial in both the US and Korea.

Sillajen is also focused on oncolytic immunotherapeutics of which our lead product is Pexa-Vec, a Phase 3-ready asset for treatment of solid tumors.

At BIO, we are seeking strategic partnering opportunities for BAL0891.